PMID- 29444603
OWN - NLM
STAT- MEDLINE
DCOM- 20181024
LR  - 20181113
IS  - 1552-695X (Electronic)
IS  - 1534-7354 (Print)
IS  - 1534-7354 (Linking)
VI  - 17
IP  - 1
DP  - 2018 Mar
TI  - Safety of Combined Treatment With Monoclonal Antibodies and Viscum album L 
      Preparations.
PG  - 41-51
LID - 10.1177/1534735416681641 [doi]
AB  - Combination strategies involving chemotherapy and monoclonal antibodies (mAb) are 
      commonly used in attempts to produce better clinical outcomes. This practice has 
      led to new and ongoing toxicities that may lead to reductions in dose or 
      noncompliance, limiting the effectiveness of treatment. Viscum album L (VA) 
      preparations are widely used in Europe as additive therapy and have been 
      associated with reduced chemotherapy-related adverse reactions and increased 
      health-related quality of life. Concomitant VA therapy might also reduce toxicity 
      related to mAb. This retrospective study investigated the safety of combined 
      treatment with VA and mAb in cancer patients. A total of 43 patients had combined 
      therapy (474 exposures); 12 had VA without mAb (129 exposures), and 8 had mAb 
      without VA (68 exposures). Most patients (89.3%) received concomitant 
      chemotherapy or supportive therapies. A total of 34 patients (60.7%) experienced 
      142 adverse events (AEs). Leucopenia (14.1% of all events), acneiform rash 
      (8.5%), and stomatitis (6.3%) occurred most frequently. Longitudinal logistic 
      regression analysis suggested a nearly 5 times higher odds of experiencing an AE 
      following treatment with mAb compared with mAb plus VA (95% CI = 1.53-16.14). Our 
      results, together with theoretical consideration of potential botanical-drug 
      interactions, suggest that combined treatment with VA and mAb is safe.
FAU - Schad, Friedemann
AU  - Schad F
AD  - 1 Research Institute Havelhoehe, Berlin, Germany.
AD  - 2 Hospital Havelhoehe, Berlin, Germany.
FAU - Axtner, Jan
AU  - Axtner J
AD  - 1 Research Institute Havelhoehe, Berlin, Germany.
FAU - Kroz, Matthias
AU  - Kroz M
AD  - 1 Research Institute Havelhoehe, Berlin, Germany.
AD  - 2 Hospital Havelhoehe, Berlin, Germany.
AD  - 3 Charite University Medical Center, Berlin, Germany.
AD  - 4 University of Witten/Herdecke, Herdecke, Germany.
FAU - Matthes, Harald
AU  - Matthes H
AD  - 1 Research Institute Havelhoehe, Berlin, Germany.
AD  - 2 Hospital Havelhoehe, Berlin, Germany.
FAU - Steele, Megan L
AU  - Steele ML
AD  - 1 Research Institute Havelhoehe, Berlin, Germany.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20161201
PL  - United States
TA  - Integr Cancer Ther
JT  - Integrative cancer therapies
JID - 101128834
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Antineoplastic Agents, Immunological)
RN  - 0 (Antineoplastic Agents, Phytogenic)
RN  - 0 (Plant Extracts)
SB  - IM
MH  - Aged
MH  - Antibodies, Monoclonal/*administration & dosage/adverse effects
MH  - Antineoplastic Agents/*administration & dosage/adverse effects
MH  - Antineoplastic Agents, Immunological/administration & dosage/adverse effects
MH  - Antineoplastic Agents, Phytogenic/administration & dosage/adverse effects
MH  - Combined Modality Therapy
MH  - Cytotoxicity, Immunologic
MH  - Female
MH  - Germany
MH  - Humans
MH  - Infusions, Intravenous
MH  - Male
MH  - Middle Aged
MH  - Neoplasms/*therapy
MH  - Phytotherapy
MH  - Plant Extracts/*administration & dosage/adverse effects
MH  - Registries
MH  - Retrospective Studies
MH  - *Viscum album
PMC - PMC5950938
OTO - NOTNLM
OT  - Helixor
OT  - Viscum album L
OT  - adverse events
OT  - combination therapy
OT  - integrative oncology
OT  - mistletoe
OT  - safety
OT  - targeted therapy
COIS- Declaration of Conflicting Interests: The author(s) declared the following 
      potential conflicts of interest with respect to the research, authorship, and/or 
      publication of this article: The Network Oncology was partially funded by Helixor 
      Heilmittel GmbH & Co. KG. By contract, researchers were independent from the 
      funder. Matthias Kroz received an honorarium for a lecture given at a Helixor 
      meeting and received a fee for a single consultation.
EDAT- 2018/02/16 06:00
MHDA- 2018/10/26 06:00
PMCR- 2016/12/01
CRDT- 2018/02/16 06:00
PHST- 2018/02/16 06:00 [entrez]
PHST- 2018/02/16 06:00 [pubmed]
PHST- 2018/10/26 06:00 [medline]
PHST- 2016/12/01 00:00 [pmc-release]
AID - 10.1177_1534735416681641 [pii]
AID - 10.1177/1534735416681641 [doi]
PST - ppublish
SO  - Integr Cancer Ther. 2018 Mar;17(1):41-51. doi: 10.1177/1534735416681641. Epub 
      2016 Dec 1.